Introduction
The doctor who prescribes a non-steroidal antiinflammatory drug (NSAID) is likely to be interested in its safety as well as its therapeutic efficacy. The area most prone to serious side effects is the gastrointestinal tract'. However, a search for scientific information yields little about the relative gastrointestinal toxicity of individual NSAIDS. With the exception of aspirin, the information has not usually been helpful to good prescribing practice.
In an authoritative leading article, Kurata and his colleagues-suggested that what we need to know is to what extent a particular drug will cause symptomatic ulceration or significant gastrointestinal bleeding. Both of these have quite a high background incidence in the general population'r' and any worthwhile studies would have to be large and sophisticated enough to overcome this. However, the vast majority of studies on individual NSAIDs have not been to the required standard" for a variety of reasons including insufficient numbers and the absence of proper control groups. These defects are compounded by a tendency for conclusions about the safety of a drug to be drawn from studies that were designed to assess its efficacy. Furthermore, many trials designed to test gastrointestinal tolerance of NSAIDs have been performed in young volunteers, even though in practice the elderly are the chief users of these drugs", This is a serious shortcoming, because older patients have most to fear in terms of mortality from peptic ulcer and its complicationsb" (Figure 1 ).
Methods of assessing safety other than clinical trials
The difficulties in mounting full clinical trials of gastrointestinal safety have led to a search for alternative, easier ways of obtaining similar information. These include short-term endoscopic studies where volunteers are examined before and after taking an NSAID for a week or so. There are many examples of this approachv '! in which drugs associated with little inflammation are presumed to be safer than those associated with gastritis or duodenitis. However, no strong evidence exists which proves the applicability of this type of study to clinical practice. It is particularly inappropriate to use symptomless mucosal appearances after short-term use in young volunteers as predictors of the risk of major adverse effects during use over longer periods in the elderly. Similar reservations are true for estimates of micro-bleeding by the radiochromate-labelled erythrocyte method's. Not only is its applicability to ordinary practice uncertain, but there are also doubts about the reliability of the technique 13 ,14. Another way of assessing the gastrointestinal safety of a drug is adverse-event reporting. The procedures involved include direct reports to the manufacturer, the 'yellow card' system in the United Kingdom" and more sophisticated methods of post-marketing surveillance such as prescription-event monitoring". These have the great advantage of being clinically based but seem most useful in detecting diseases which are otherwise uncommon. Indeed, they should help minimize catastrophies such as were associated with thalidomide and practolol. However, they are less likely to be helpful where a drug is suspected of causing a common disease. Peptic ulcer is relatively common, with a background incidence in the general population of about 0.2% per annums. This means that the significance ofcases of peptic ulcer occurring in users of the drug is uncertain. In addition, the great variability of reporting and the absence of control groups means that these methods will not be able to yield precise estimates of relative risk.
Recently, the Committee on Safety of Medicines (CSM) produced details of reports on the different NSAIDs in the United Kingdom (Table 1 ).This information represents an advance, because a sense of proportion is introduced by detailing how frequently the drugs were used. However, even this and the very large numbers involved do not entirely overcome the shortcomings of adverse-event reporting mentioned above. The CSM quite rightly only draws the broadest of conclusions when using the information'. It estimates that 5 products -benoxaprofen, fenclofenac, feprazone, indoprofen and Osmosin (a brand of slowrelease indomethacin) -appear to be substantially more toxic than others. Ibuprofen appears to be less toxic at least in low dose. The CSM felt that 'the safety of the remaining drugs cannot be clearly distinguished from each other on the basis of these reports'. In 1980 a review concluded that anecdotal reports abound but there is no evidence that NSAIDs, other than aspirin, cause peptic ulcer-", From a scientific viewpoint, that statement still holds true as far as individual drugs are concerned. However, recent studies in elderly subjects have demonstrated statistically significant associations between use of members of the NSAID group and bleeding ulcers'", symptomatic peptic ulcerations" and perforated ulcers'", Of course these associations do not necessarily prove cause and effect. To decide whether such an association represents causation, the noted epidemiologist Bradford-Hill gave helpful guidelines 22 • Applying them to these studies and to the literature as a whole suggests that they represent cause and effect. Assuming, then, a causal relationship, the risk of users of non-aspirin NSAIDs aged over 60 developing a symptomatic peptic ulcer is increased by a factor of about 5 20 and the risk of a bleeding ulcer more than doubled'", Unfortunately, similar estimates of relative risk are not available for individual NSAIDs. Case reports of individuals who have used various NSAIDs developing ulcers continue to appear in medical journals. These reports of themselves prove nothing, though they can serve a useful purpose in highlighting the need for further scientific evaluation of the drug in question. However, the limits of case reporting in a disease with a high background incidence can be easily lost when they reach the lay media. The controversy surrounding benoxaprofen (Opren) is still relatively fresh in public minds, and even balanced media speculation about other commonly used NSAIDs such as piroxicam'P causes concern. Furthermore, the knowledge that quite a few members of this drug group have been withdrawn over the last five years can foster a feeling of 'which next?'. In this atmosphere of uncertainty, the lack of scientific literature on side effects of NSAIDs is particularly felt. There thus remains a major need for precise information on the gastrointestinal side effects of the great majority of NSAIDs.
What would constitute a good trial of gastrointestinal safety? Until some of the simpler methods of drug evaluation mentioned above have been shown to relate closely to clinical practice, precise information will have to be sought elsewhere. At present the choice seems to lie between prospective studies and case evaluation methods like the BCDSP. Though the latter have yielded useful results with aspirin, they are retrospective in nature and are subject to biases that are difficult to control 24 • Confirmation of their findings by a prospective work would help remove these doubts.
Prospective studies should be more accurate at least in theory. The reasons why they have not been satisfactorily performed already include worries that all patients would have to be endoscoped routinely and the difficulty in finding valid control groups. The considerable expense that would be involved has probably also been a factor. However, these reservations are not insurmountable. First, the endoscopy of every patient would be unnecessary as the information required concerns ulcers that are clinically significant. Routine endoscopy to detect asymptomatic lesions would not, therefore, be indicated. What would be needed in a trial situation is easy access to endoscopy with a high index of suspicion for the presence of peptic ulceration. In particular, the tendency for older patients with ulcers not to have abdominal pain 25 • 26 means that other pointers would have to be considered. For example, vomiting, weight loss and unexplained anaemia might suggest the need for examination.
Identifying a valid control group should not present a major problem. NSAIDs are not lifesaving drugs. It is quite ethical for some patients with arthritic conditions to be on no medication or pure analgesics which are not suspected of causing peptic ulcer. The ulcerogenicity of a NSAID could thus be assessed by comparison of the incidence of ulceration in users of the drug with a control group containing a similar range of diseases. This would make the conclusions of the study more acceptable, since there is a widely held belief that some conditions such as rheumatoid arthritis 27 are associated with a higher incidence of peptic ulceration. These probably often represent false asaoclationst, and controls which are not closely disease-matched have been used with no apparent loss of validity-".
Large numbers would be required for any proper trial. Kurata and his colleagues-estimated that to detect a five-fold increase in the ulcerogenicity of a
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prescriptions Drug drug would require 1600 patients in both ulcer and control groups. This assumes a background incidence of peptic ulcer of 0.2% per annum. However, NSAID users tend to have a high average age and there is evidence to suggest that ulcer disease may occur more frequently in the elderly'", So a study that would be representative of clinical practice might require close to 2000 in each group. The duration of the trial would have to be at least six months and preferably a year. In one analysis, 74% of NSAID-associated ulcers occurred within six months of starting the drug 20 •
Conclusion
The requirements for definitive trials seem to involve large numbers and considerable trouble and expense. The question of whether it is worthwhile could be raised. Several factors suggest that it would be of great value to perform at least one such study. First, the fact that the elderly are the chief users of NSAIDs means that drugs that are potent causes of ulceration will probably be associated with a significant mortality <Figure 1). Precise estimates ofthe capacity of individual drugs to cause ulcers and bleeding would thus seem to be essential information, at least for safe prescribing in older patients. Secondly, an authoritative trial would serve as a sound basis on which to estimate the reliability of less elaborate predictive procedures. Finally, a scientific trial would yield information that would be worthy of publication in leading medical journals. This would be in sharp contrast to previous practice whereby much of the literature in this field was published in obscure journals or in proceedings of symposia without strict editorial review. High quality would help restore public confidence in the safety of drug-monitoring procedures. Much of the uproar that occurred at the time of the withdrawal of benoxaprofen resulted from a lack of hard information with which to counter some of the wilder media speculation. Resources spent on assessment of at least one NSAID would thus seem justifiable. Piroxicam, naproxen or indomethacin seem to be leading candidates for such a trial.
